What is adagrasib used to treat?

Adagrasib (Adagrasib), sold under the brand name Krazati, is an anticancer drug used to treatnon-small cell lung cancer and colorectal cancer. Adagrasib is an inhibitor of the KRAS GTPase family. It was approved in the United States for the treatment of lung cancer in December 2022 and for the treatment of colorectal cancer in 2024 with cetuximab.

Adagrasib is an irreversible inhibitor of KRAS G12C that covalently binds to the mutated cysteine in KRAS G12C and locks the mutated KRAS protein in an inactive state, preventing downstream signaling without affecting wild-type KRAS protein. Adagarasib inhibits tumor cell growth and viability in cells harboring the KRAS G12C mutation and causes tumor regression in a KRAS G12C-mutated tumor xenograft model with minimal off-target activity. Compared with adagrasiib or cetuximab alone, adagrasiib plus cetuximab had enhanced antitumor activity in some cell line-derived and patient-derived xenograft models of KRAS G12C-mutant CRC tumors.

However, like all medications, adagrasib has the potential to cause some adverse reactions. The most common adverse reactions include gastrointestinal symptoms such as nausea, diarrhea, and vomiting, as well as other symptoms such as fatigue and musculoskeletal pain. In addition, there are some less common but potentially more serious adverse reactions, such as liver damage and difficulty breathing. Therefore, patients should pay close attention to their own reactions during use and provide timely feedback to their doctors.

In general, adagrasib, as a new treatment for non-small cell lung cancer and colorectal cancer, provides new hope for patients with KRAS G12C mutations. Its mechanism of action and therapeutic effect make it play an important role in the field of lung cancer treatment. With the deepening of research and accumulation of clinical practice, we believe that adagrasib will bring good news to more patients.